Detalhe da pesquisa
1.
Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
Am J Respir Crit Care Med
; 200(7): 857-868, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046405
2.
Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD.
Eur Respir J
; 53(3)2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30655277
3.
Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial.
Respir Res
; 20(1): 237, 2019 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665017
4.
Sustained 24-hour efficacy of once daily indacaterol (300 µg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
Pulm Pharmacol Ther
; 24(1): 162-8, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20619353
5.
Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons.
J Inflamm Res
; 14: 4503-4507, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34522118
6.
Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
Chest
; 129(3): 509-17, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16537846
7.
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
Int J Chron Obstruct Pulmon Dis
; 11: 687-96, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27099485
8.
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting ß2-agonist, in patients with chronic obstructive pulmonary disease.
Respir Med
; 109(5): 606-15, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25776199
9.
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Int J Chron Obstruct Pulmon Dis
; 9: 215-28, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24596459